Valuation: Semler Scientific, Inc.

Market Cap 232M 4.18B 204M 193M 175M 329M 22.23B 333M 2.31B 890M 11.36B 870M 851M 36.43B P/E 2023
16.8x
P/E 2024 10.5x
Enterprise Value 217M 3.91B 191M 181M 163M 308M 20.8B 312M 2.17B 833M 10.63B 815M 797M 34.09B EV / Sales 2023
3.53x
EV / Sales 2024 8.63x
Free-Float
97.04%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 01/12/2022
Corporate Secretary 45 16/01/2026
Director TitleAgeSince
Director/Board Member 41 16/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-31.15%-40.33% - - 311M
-1.60%-3.78%-25.66%+4.02% 175B
-0.58%-2.81%-8.87%+11.60% 111B
-1.05%+0.72%-25.51%+0.56% 107B
+0.69%-2.90%-47.25%-11.04% 75.31B
-1.52%-2.74%-2.82%+69.61% 58.7B
-1.08%-1.19%-3.65%-30.04% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-1.57%+0.84%-17.61%+22.15% 42.02B
-0.32%-1.16%+28.87%-8.29% 32.69B
Average -3.65%-0.69%-9.61%+12.49% 77.84B
Weighted average by Cap. -0.77%-1.13%-15.86%+10.18%

Financials

2023 2024
Net sales 68.18M 1.23B 60.04M 56.89M 51.36M 96.8M 6.54B 98.05M 681M 262M 3.34B 256M 250M 10.72B 56.29M 1.01B 49.57M 46.97M 42.4M 79.92M 5.4B 80.95M 562M 216M 2.76B 211M 207M 8.85B
Net income 20.58M 371M 18.13M 17.17M 15.5M 29.22M 1.97B 29.6M 205M 79.07M 1.01B 77.29M 75.6M 3.23B 40.9M 737M 36.02M 34.12M 30.81M 58.06M 3.92B 58.81M 408M 157M 2B 154M 150M 6.43B
Net Debt -57.04M -1.03B -50.23M -47.59M -42.96M -80.97M -5.47B -82.02M -569M -219M -2.8B -214M -210M -8.96B -14.85M -268M -13.08M -12.39M -11.18M -21.08M -1.42B -21.35M -148M -57.04M -728M -55.76M -54.54M -2.33B
Logo Semler Scientific, Inc.
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Employees
79